In plain English
Vaxcyte Inc. develops biologic medicines, focusing on a 31‑valent pneumococcal vaccine called VAX‑131. The company’s Phase 3 OPUS‑11 trial…
Company stock · NASDAQ NMS - GLOBAL MARKET · USD
PCVX
Vaxcyte Inc
—
Price unavailable — company details still show below
- Industry
- Biotechnology
- Market value
- $9.5 billion
- Number of shares
- 152.2 million
- Country
- US
- Went public
- Jun 12, 2020
- Exchange
- NASDAQ NMS - GLOBAL MARKET
- Website
- vaxcyte.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What PCVX is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
2 recent cards — open any for the full deeper dive.
Vaxcyte Stock Hits New 52-Week High - Here’s Why
In brief
Vaxcyte’s OPUS‑1 success could fast‑track a 31‑valent vaccine and lift its stock sharply.
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
In brief
Analysts updated price targets for a dozen stocks on Monday, including a modest $5 lift for Alphabet Inc.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for PCVX will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.